Brandon Eilertson1, Fernanda Maruri2, Amondrea Blackman2, Yan Guo3, Miguel Herrera4, Yuri van der Heijden2, Yu Shyr3, Timothy R Sterling5. 1. Division of Infectious Diseases, Department of Medicine, State University of New York Downstate, New York, NY, USA Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA. 2. Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA Vanderbilt Tuberculosis Center, Vanderbilt University School of Medicine, Nashville, TN, USA. 3. Vanderbilt Center for Quantitative Sciences, Vanderbilt University School of Medicine, Nashville, TN, USA. 4. Vanderbilt Technologies for Advance Genomics, Vanderbilt University Medical Center, Nashville, TN, USA. 5. Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA Vanderbilt Tuberculosis Center, Vanderbilt University School of Medicine, Nashville, TN, USA timothy.sterling@vanderbilt.edu.
Abstract
BACKGROUND: Fluoroquinolone resistance in Mycobacterium tuberculosis is often conferred by DNA gyrase mutations. However, a substantial proportion of fluoroquinolone-resistant M. tuberculosis isolates do not have such mutations. METHODS: Ofloxacin-resistant and lineage-matched ofloxacin-susceptible M. tuberculosis isolates underwent WGS. Novel candidate resistance mutations were confirmed by Sanger sequencing and conferral of resistance was assessed via site-directed mutagenesis and allelic exchange. Ofloxacin MIC was determined by resazurin microtitre assay (REMA) and the effects on MICs of efflux pump inhibitors (CCCP, reserpine and verapamil) were determined. RESULTS: Of 26 ofloxacin-resistant isolates, 8 (31%) did not have resistance-conferring DNA gyrase mutations. The V762G mutation in Rv1783 (eccC5, encoding a protein in the ESX-5 membrane complex secretion system) was present on WGS in 8/26 (31%) resistant isolates and 0/11 susceptible isolates (P = 0.005). The mutation was identified in five isolates without DNA gyrase mutations and three isolates with such mutations; it was identified in both European-American and East Asian M. tuberculosis lineages. The ofloxacin MIC increased from 1 to 32 mg/L after introduction of the V762G mutation into M. tuberculosis H37Rv. In this strain with the V762G mutation, ofloxacin MIC did not change in the presence of efflux pump inhibitors. CONCLUSIONS: A novel V762G mutation in Rv1783 conferred ofloxacin resistance in M. tuberculosis by a mechanism other than drug efflux. This occurred in a substantial proportion of resistant isolates, particularly those without DNA gyrase mutations.
BACKGROUND:Fluoroquinolone resistance in Mycobacterium tuberculosis is often conferred by DNA gyrase mutations. However, a substantial proportion of fluoroquinolone-resistant M. tuberculosis isolates do not have such mutations. METHODS:Ofloxacin-resistant and lineage-matched ofloxacin-susceptible M. tuberculosis isolates underwent WGS. Novel candidate resistance mutations were confirmed by Sanger sequencing and conferral of resistance was assessed via site-directed mutagenesis and allelic exchange. Ofloxacin MIC was determined by resazurin microtitre assay (REMA) and the effects on MICs of efflux pump inhibitors (CCCP, reserpine and verapamil) were determined. RESULTS: Of 26 ofloxacin-resistant isolates, 8 (31%) did not have resistance-conferring DNA gyrase mutations. The V762G mutation in Rv1783 (eccC5, encoding a protein in the ESX-5 membrane complex secretion system) was present on WGS in 8/26 (31%) resistant isolates and 0/11 susceptible isolates (P = 0.005). The mutation was identified in five isolates without DNA gyrase mutations and three isolates with such mutations; it was identified in both European-American and East Asian M. tuberculosis lineages. The ofloxacin MIC increased from 1 to 32 mg/L after introduction of the V762G mutation into M. tuberculosis H37Rv. In this strain with the V762G mutation, ofloxacin MIC did not change in the presence of efflux pump inhibitors. CONCLUSIONS: A novel V762G mutation in Rv1783 conferred ofloxacin resistance in M. tuberculosis by a mechanism other than drug efflux. This occurred in a substantial proportion of resistant isolates, particularly those without DNA gyrase mutations.
Authors: Anandi Martin; Fabienne Paasch; Sven Docx; Krista Fissette; Belen Imperiale; Wellman Ribón; Liliana Andrea González; Jim Werngren; Anna Engström; Girts Skenders; Pontus Juréen; Sven Hoffner; Patricia Del Portillo; Nora Morcillo; Juan Carlos Palomino Journal: J Antimicrob Chemother Date: 2011-01-19 Impact factor: 5.790
Authors: Edith N G Houben; Jovanka Bestebroer; Roy Ummels; Louis Wilson; Sander R Piersma; Connie R Jiménez; Tom H M Ottenhoff; Joen Luirink; Wilbert Bitter Journal: Mol Microbiol Date: 2012-08-27 Impact factor: 3.501
Authors: E Mazars; S Lesjean; A L Banuls; M Gilbert; V Vincent; B Gicquel; M Tibayrenc; C Locht; P Supply Journal: Proc Natl Acad Sci U S A Date: 2001-02-13 Impact factor: 11.205
Authors: S T Cole; R Brosch; J Parkhill; T Garnier; C Churcher; D Harris; S V Gordon; K Eiglmeier; S Gas; C E Barry; F Tekaia; K Badcock; D Basham; D Brown; T Chillingworth; R Connor; R Davies; K Devlin; T Feltwell; S Gentles; N Hamlin; S Holroyd; T Hornsby; K Jagels; A Krogh; J McLean; S Moule; L Murphy; K Oliver; J Osborne; M A Quail; M A Rajandream; J Rogers; S Rutter; K Seeger; J Skelton; R Squares; S Squares; J E Sulston; K Taylor; S Whitehead; B G Barrell Journal: Nature Date: 1998-06-11 Impact factor: 49.962
Authors: Louis S Ates; Roy Ummels; Susanna Commandeur; Robert van de Weerd; Robert van der Weerd; Marion Sparrius; Eveline Weerdenburg; Marina Alber; Rainer Kalscheuer; Sander R Piersma; Abdallah M Abdallah; Moataz Abd El Ghany; Alyaa M Abdel-Haleem; Arnab Pain; Connie R Jiménez; Wilbert Bitter; Edith N G Houben Journal: PLoS Genet Date: 2015-05-04 Impact factor: 5.917
Authors: Thurston Herricks; Magdalena Donczew; Fred D Mast; Tige Rustad; Robert Morrison; Timothy R Sterling; David R Sherman; John D Aitchison Journal: Elife Date: 2020-05-13 Impact factor: 8.140
Authors: Francisco Olivença; Alexandra Nunes; Rita Macedo; David Pires; Cátia Silveiro; Elsa Anes; Maria Miragaia; João Paulo Gomes; Maria João Catalão Journal: Microbiol Spectr Date: 2022-06-13
Authors: Amondrea Blackman; Bob Morrison; Fernanda Maruri; Yuri van der Heijden; Cindy Hager Nochowicz; Yan Guo; Matthew Scholz; Tige Rustad; David R Sherman; Timothy R Sterling Journal: J Antimicrob Chemother Date: 2021-02-11 Impact factor: 5.790